12:34:47 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-linea är verksamma inom medicinteknik. Bolaget är specialiserade inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har sitt huvudkontor i Uppsala.

Kalender

2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 Ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2021-03-31 14:21:00

Q-linea AB (publ) (OMX: QLINEA) today announced very good interim results from the pivotal European trial for the antibiotic susceptibility system ASTar®. EA was over 94 percent, CA over 97 percent and overall reproducibility over 99 percent. To achieve CE-IVD approval in Europe, EA and CA must exceed 90 percent.

Q-linea has analyzed the results from the majority of the samples in the clinical study and the interim results look very good. Q-linea will continue to analyze samples and collect samples from the clinic but does not foresee that the final analysis will deviate negatively from these results.

Essential Agreement (EA) i.e. giving the same result as the reference method on the concentration of antibiotics that kill or inhibit bacterial growth exceeded 94 percent. Categorical agreement (CA) i.e. giving the same classification of the bacterium within one of three groups (S.I.R) with respect to susceptibility to antibiotics exceeded 97 percent. To achieve CE-IVD approval in Europe, EA and CA must exceed 90 percent. In addition, reproducibility was very high and exceeded 99 percent.

“We are of course very happy that the interim results are so strong. We now have the data we need for the pivotal European study for ASTar. What remains is the completion of the technical file for CE-IVD registration and the completion of certain validation activities, but with these positive results, all launch activities can continue at an increased pace. The fact that we have included difficult and important antibiotics such as Colistin and fastidious bacteria shows that our technology is well prepared for the future," said Jonas Jarvius, CEO of Q-linea.

ASTar is a fully automatic and user-friendly system for antibiotic susceptibility testing (AST) with a short hands-on time and the capability to deliver a broad answer within approximately six hours for positive blood cultures.